\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Alteration of Thyroid Hormone Pictures in Absence of Clinically Evident Thyroid Diseases among Type 2 Diabetic Subjects in a Bangladeshi Population},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2021-05-15 (revised: 15 May 2021)}
\def\TheID{\makeatother }
\def\TheDate{2021-05-15}
\title{Alteration of Thyroid Hormone Pictures in Absence of Clinically Evident Thyroid Diseases among Type 2 Diabetic Subjects in a Bangladeshi Population}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Dr. Sheikh Anwarul  Karim}

             \author[2]{J  Samira}

             \author[3]{SMR  Raihan}

             \author[4]{MS  Emran}

             \author[5]{O  Faroque}

             \author[6]{L  Ali}

\renewcommand\Authands{ and }

\date{\small \em Received: 6 April 2021 Accepted: 3 May 2021 Published: 15 May 2021}

\maketitle


\begin{abstract}
        


Background: Thyroid diseases and diabetes mellitus are common endocrine disorders and Euthyroid Sick Syndrome is very common in uncontrolled type2 Diabetes Mellitus.Objective: To evaluate the thyroid hormone pictures in absence of clinical thyroid diseases among type2 diabetic subjects in a Bangladeshi population.

\end{abstract}


\keywords{euthyroid sick syndrome (ESS), diabetes mellitus, body mass index (BMI).}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
iabetes mellitus (DM) is one of the important health problems affecting the major population worldwide. Diabetes mellitus is an endocrine disorder which involves multiple organ systems and leads to significant morbidity and mortality due to accompanying complications.  {\ref 1.} Diabetes mellitus is characterized by absolute or relative deficiency in insulin secretion or insulin action or both, associated with hyperglycemia and disturbances in carbohydrate, lipid and protein metabolism. \hyperref[b1]{2} Thyroid diseases and diabetes mellitus are the two most common endocrine disorders \hyperref[b3]{3} . Diabetic patients have increased prevalence of thyroid disorder, with hypothyroidism being the most common. \hyperref[b4]{4} In diabetic patients, thyroid dysfunction varies from 2.2\% -17\%.\par
Diabetic women are more commonly affected than men. \hyperref[b5]{5} Hypothyroidism is a clinical syndrome occurs from a deficiency of thyroid hormones. It is very common thyroid problem in diabetic patients. \hyperref[b6]{6} Thyroid hormones and insulin are the antagonistic, and involved in the metabolism of carbohydrates, proteins, and lipids. Thyroid hormone as well as insulin levels are altered if there is functional impairment of the thyroid gland and endocrine pancreatic beta cells. \hyperref[b7]{7} Thyroid disorders adversely affect diabetes control. Diabetes Mellitus appears to influence thyroid function in two sites; firstly, at the level of hypothalamic control of TSH release and secondly at the conversion of T 4 to T 3 in the peripheral tissue. Increased hyperglycemia causes reversible reduction of the activity and hepatic concentration of T 4 -5?-deiodinase, low serum T 3 , increase in reverse T 3 and also variation in the level of T 4 . \hyperref[b8]{8} Euthyroid Sick syndrome (ESS) or Non-thyroidal illness Syndrome (NTIS) identifies abnormalities of thyroid function tests observed in patients with systemic nonthyroidal illnesses and in those patients undergoing surgery or fasting. \hyperref[b9]{[9]}\hyperref[b10]{[10]}\hyperref[b11]{[11]} Abnormalities of thyroid function tests observed in ESS or NTIS includes 1) Low T 3 Syndrome 2) Low T 3 and T 4 syndrome 3) High TT 4 syndrome 4) other abnormalities like low TT 3 and TSH, high TSH and low TT 3 and TT 4 . \hyperref[b12]{12} A previous study among young Bangladeshi diabetic population demonstrated significant alteration of thyroid hormone pictures in absence of clinical thyroid diseases which is consistent with the other study done in abroad earlier. \hyperref[b22]{22} But ESS or NTIS in the setting of type2 diabetes was not investigated extensively earlier and there is no available data regarding the changes in thyroid hormone pictures in patients with uncontrolled type2 Diabetes Mellitus among Bangladeshi population. Although there are few studies in abroad; which revealed that that there are significant alteration of thyroid hormones in uncontrolled type2 diabetic subjects. \hyperref[b19]{19,}\hyperref[b20]{20,}\hyperref[b23]{23,}\hyperref[b24]{24} As most of these studies did not exclude other causes of ESS or NTIS which are responsible for activating inner ring deiodination or inhibition of outer ring deiodination of T 4 to produce T 3 from T 4 instead of rT 3 ; 25 the result was found to be poorly representative.\par
In the above context our present study was designed to document the changes of thyroid hormones pictures in absence of clinical thyroid diseases among Bangladeshi population in the setting of uncontrolled type2 diabetes mellitus. 
\section[{II.}]{II.} 
\section[{Objectives and Methods}]{Objectives and Methods}\par
To evaluate the circulating thyroid hormone pictures in absence of clinical thyroid diseases among type 2 diabetic subjects in a group of Bangladeshi population. 
\section[{III.}]{III.} 
\section[{Methodology a) Types of study}]{Methodology a) Types of study}\par
This was a case and control study. 
\section[{b) Place and duration of study}]{b) Place and duration of study}\par
The study was conducted in the Endocrinology department of Sylhet MAG Osmani Medical College (SOMC) and Hospital, Sylhet, Bangladesh in collaboration with the Research Division, BIRDEM, Dhaka, Bangladesh during the period of January 2016 to December 2017. 
\section[{c) Study population}]{c) Study population}\par
A total of 100 type 2 diabetic subjects, 30-50 years of age, irrespective of glycemic status, duration of diabetes, BMI and sex were recruited from the outpatient department (OPD) of SOMC hospital and BIRDEM hospital. Prior to recruitment, diabetes mellitus was confirmed according to current American Diabetic Association (ADA) criteria for the diagnosis and classification of diabetes mellitus. \hyperref[b24]{24} Control subjects (n=100) were selected from friends and family of the patients within 5 years of age band without diabetes or impaired glucose regulation (IFG, IGT) determined according to ADA criteria \hyperref[b24]{24} and having no clinical thyroid diseases or other evident systemic diseases documented on clinical evaluation. Informed written consent was taken from all recruited diabetic and control subjects for the purpose of the study. 
\section[{d) Exclusion criteria}]{d) Exclusion criteria}\par
? Type 2 diabetes with acute metabolic decompensation. Experiments on both animal and human models Diabetes Mellitus was found to be associated with alteration of thyroid hormone picture in absence of clinical thyroid diseases irrespective of the type of diabetes. In both type1 and type2 diabetes significant reduction of both TT 3 and FT 3 , increased rT 3 and high rT 3 /T 3 ratio was demonstrated. \hyperref[b13]{[13]}\hyperref[b14]{[14]}\hyperref[b15]{[15]}\hyperref[b16]{[16]} Serum FT 4 and FT 4 I were normal, TT 4 was normal or suppressed and TSH was found normal or slightly elevated. \hyperref[b17]{17,}\hyperref[b18]{18} All the parameters of thyroid function specially TT 3 , FT 3 and rT 3 become normal when euglycemia was achived. \hyperref[b14]{14,}\hyperref[b19]{19,}\hyperref[b20]{20} More over it was found that reduction of FT 3 and TT 3 , rise of rT 3 are significantly correlated with the severity of hyperglycemia and the thyroid secretory response to large dose of TSH is also declined in uncontrolled diabetes mellitus which frequently improves with improved glycemic control. \hyperref[b21]{21}   
\section[{Medical}]{Medical} 
\section[{e) Method}]{e) Method}\par
Selection criteria as per availability and was given an appointment to come in a particular date. Preparation of the subjects and collection of blood of the Controls and diabetic subjects that were assigned for the purpose of study done according to the recommendation of the "Report of the Expert committee of the Diagnosis and Classification of Diabetes Mellitus. \hyperref[b24]{24} They were requested to fast overnight for at least eight hours and in the subsequent morning 16 ml of venous blood was drawn from the ante-cubital vein by using 25 cc disposable plastic syringe with 18G needle for the estimation of fasting serum insulin, C-peptide, glucose, HbAlc, TT 3 , TT 4 , FT 3 , FT 4 and TSH. One ml of collected venous blood was taken in an anticoagulant containing vial for estimation of HbAlc. Remaining 15ml of blood was kept in 3 separate plain test tubes in equal amounts (5ml in each) to centrifuge immediately. Blood sample contained in the test tube was centrifuged for 15 minutes at a rate of 4000 rpm. A total of 200 µl of serum was collected in appropriately labeled eppendorf in duplicate with the help of micropipette for each of the biochemical parameters. Then the serum sample was preserved immediately at -30° C for analysis. 
\section[{f) History and clinical examination}]{f) History and clinical examination}\par
Detailed socio-demographic and clinical data were recorded in a pre-designed case record form. These include age, sex, residing area, occupation, socioeconomic status, dietary habit, exercise, alcohol and smoking habit, duration of diabetes, associated diseases like hypertension, obesity, dyslipidemia, coronary artery disease, cerebrovascular diseases, peripheral vascular diseases and crystal deposition diseases. Family history of these diseases were also been noted. Classical and non-classical features of diabetes mellitus and any adverse outcome of diabetes on life style was noted by taking history from the diabetic subjects.\par
Hight, weight, BMI, waist circumference, hip circumference, waist hip ratio (WHR), waist height ratio (WHtR) of all the controls and diabetic subjects were recorded. Percent body fat and total fat mass was measured by "Body logic Body fat monitor; Omron Corporation, Japan". Systolic and diastolic blood pressure of all patients and control subjects was recorded. Blood pressure was measured by using mercury sphygmomanometer after at least 5 minutes of recumbence in a calm and quiet environment. Systolic blood pressure 130 mm Hg and the diastolic blood pressure 85 mm Hg was taken as the cut-off value for categorizing the normal and the abnormal values among diabetic population. \hyperref[b25]{25}   
\section[{g) Statistical analysis}]{g) Statistical analysis}\par
All the data were expressed as mean standard deviation, median (range) and/or number and percentage (\%) as appropriate. Statistical analysis was done by using SPSS 7.5 packages for windows. Appropriate statistical test of significance like unpaired t test, one way analysis of variance (ANOVA) and Mann-Whitney test was used as necessary. P < 0.05 was taken as minimum level of significance. 
\section[{h) Data presentation}]{h) Data presentation}\par
Tabulation and / or drawing either in the form of graph or in the form of diagram were utilized as necessary for data presentation.\par
IV. 
\section[{Results}]{Results}\par
Table     
\section[{(BMI A=BMI upto 25). (BMI B=BMI 25.1-30). (BMI C=BMI>30) (P value was calculated by ANOVA Bonferrony, U/p value was calculated using Mann-Whitney U test)}]{(BMI A=BMI upto 25). (BMI B=BMI 25.1-30). (BMI C=BMI>30) (P value was calculated by ANOVA Bonferrony, U/p value was calculated using Mann-Whitney U test)}\par
Table-6 showed that when TT 3 , TT 4 , FT 3 , FT 4 and TSH were grouped according to BMI category and compared separately among control and Diabetic subjects in three BMI groups; no significant difference was observed.     
\section[{Discussion}]{Discussion}\par
Some studies done earlier in abroad; the age (mean±SD) of type 2 diabetic patients who were participated in study was (47.5±7.4) years coincides with the fact that type 2 diabetes mellitus usually develops after the age 40 years. \hyperref[b9]{9,}\hyperref[b26]{26,}\hyperref[b27]{27} . Where as in our study age (mean±SD) of the control and diabetic subjects were 39.5±5.2 and 39.2±5.8 respectively. Thyroid hormones among control and Diabetic subjects was evaluated and it was found that the differences observed in serum thyroid hormones and TSH levels between controls and diabetic subjects were not statistically significant. When the thyroid hormones and TSH were reevaluated on the basis of BMI and HbAlc groups among the diabetic subjects, similar observation was noted (table \hyperref[tab_5]{5 and 6}). But when serum TT  19, 20). This finding is consistent with the findings of the other studies done in abroad in both type 1 and type 2 diabetic subjects. \hyperref[b11]{[11]}\hyperref[b12]{[12]}\hyperref[b13]{[13]}\hyperref[b14]{[14]}\hyperref[b15]{[15]}\hyperref[b16]{[16]}\hyperref[b28]{[28]}\hyperref[b29]{[29]}\hyperref[b31]{[30]}\hyperref[b32]{[31]} . Our findings showed that around the level of 12mmoll of fasting serum glucose was associated with marked alteration of thyroid hormone picture in the blood in absence of clinical thyroid diseases. When low TT 3 group was categorized according to BMI, diabetic subjects having BMI within normal range was found to have more deteriorating fasting serum glucose, HbA1c and serum TT 3 levels; compare to other BMI groups (Table \hyperref[tab_8]{-8}). This finding suggests that changes in thyroid hormone possibly much more obvious in young diabetic groups who are mostly have low or normal BMI than the type2 diabetic subjects that are mostly associated with obesity and higher degrees of BMI. These findings also supports the findings of the others study done in abroad. \hyperref[b21]{21} and also in the cell and molecular biology department of BIRDEM, Dhaka, Bangladesh. \hyperref[b22]{22} Our findings also conclude that BMI and other indices of obesity possibly have very little or no impact on serum thyroid hormones and TSH levels until and unless they are associated with very high serum fasting glucose levels beyond 12mmol/l.\par
VI. 
\section[{Conclusion}]{Conclusion}\par
1. Uncontrolled type 2 diabetes mellitus is associated with alteration of thyroid hormone pictures particularly altering the TT 3 , FT 3 and TSH in absence of clinically evident thyroid diseases. 2. This biochemical feature is more evident if the BMI of the subjects is low or normal range and it was also found that the more worsening the glycemic status as determined by FPG and HbA1c, there was more deteriorating circulating serum thyroid hormone pictures and TSH. 3. Interpretation of abnormal thyroid hormone pictures requires a very high index suspicion in patients with uncontrolled type2 diabetes mellitus as it was found to have associated with ESS or NTIS.\begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_0}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-3.png}
\caption{\label{fig_1}Figure- 1 :}\end{figure}
   \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.13289085545722715\textwidth}P{0.11533923303834807\textwidth}P{0.22315634218289082\textwidth}P{0.08023598820058997\textwidth}P{0.11784660766961652\textwidth}P{0.0827433628318584\textwidth}P{0.09778761061946903\textwidth}}
Groups\tabcellsep Age mean ± SD\tabcellsep Annual Income Median (Range)\tabcellsep Family Member\tabcellsep SBP mean ± SD\tabcellsep DBP mean ± SD\tabcellsep Duration of DM, years\\
Controls (n =30)100\tabcellsep 39.53± 5.24\tabcellsep 120000 (30000-220000)\tabcellsep 6 ±1\tabcellsep 120 ±23\tabcellsep 80±7\tabcellsep --\\
DM(n=100)\tabcellsep 39.24± 5.79\tabcellsep 100000 (20000-200000)\tabcellsep 6± 2\tabcellsep 124 ±17\tabcellsep 80±10\tabcellsep 0.02 (0.01-6 )\\
\multicolumn{2}{l}{t/p value}\tabcellsep u/p value\tabcellsep \tabcellsep \multicolumn{2}{l}{t/p value}\tabcellsep \\
Cont vs DM\tabcellsep -.248/0.804\tabcellsep 1114/0.32*\tabcellsep 1.1770/.241\tabcellsep 1.177/0.241\tabcellsep 1.101/0.273\tabcellsep --\end{longtable} \par
  {\small\itshape [Note: In table-1 shows demographic status of the study group where mean±SD age of the control and diabetic subjects were 39.5±5.2 and 39.2±5.8 respectively. Duration of diabetes is one month to six years. Systolic and diastolic blood pressure of the control and diabetic subjects were almost similar and it was within normal range. The table given below showed it in detail:]} 
\caption{\label{tab_2}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{-} \par 
\begin{longtable}{P{0.604296875\textwidth}P{0.03907752403846154\textwidth}P{0.04546274038461538\textwidth}P{0.12642728365384617\textwidth}P{0.0025540865384615385\textwidth}P{0.0025540865384615385\textwidth}P{0.010216346153846154\textwidth}P{0.01941105769230769\textwidth}}
\multicolumn{7}{l}{Alteration of Thyroid Hormone Pictures in Absence of Clinically Evident Thyroid Diseases among Type 2}\\
\tabcellsep \tabcellsep \multicolumn{5}{l}{Diabetic Subjects in a Bangladeshi Population}\\
\tabcellsep \multicolumn{2}{l}{H/O CVD}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 06\tabcellsep 6\\
\tabcellsep \multicolumn{2}{l}{Retinopathy}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 35\tabcellsep 35\\
\tabcellsep \multicolumn{2}{l}{Neuropathy}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 35\tabcellsep 35\\
\tabcellsep \multicolumn{2}{l}{Nephropathy}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 25\tabcellsep 25\\
\tabcellsep \multicolumn{2}{l}{Anti DM drugs}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 24\tabcellsep 24\\
\tabcellsep \multicolumn{2}{l}{Typical Symptoms}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 37\tabcellsep 37\\
\tabcellsep \multicolumn{2}{l}{Atypical Symptoms}\tabcellsep Present\tabcellsep 0\tabcellsep 0\tabcellsep 63\tabcellsep 63\\
\tabcellsep \tabcellsep \multicolumn{5}{l}{Table-3: Thyroid hormone status in diabetic and control subjects}\\
Parameters TT 3 TT 4 FT 3 FT 4 TSH\tabcellsep MC** 93.67± 17.14 8.54± 1.9 2.69 ±0.36 1.49 ±0.21 ± 0.88 1.33\tabcellsep Control FC** 83.46 ±12.78 8.07± 1.31 2.56 ±0.55 1.37 ±0.23 ±1.16 1.35\tabcellsep \multicolumn{4}{l}{DM TC** MD** FD** TD** MCvs MD FC vs FD TC vs TD MD vs FD P value 88.91 ±15.88 85.02 ±22.7 83.46 ±22.0 84.27 ±22.3 0.912 1.00 -1.268 /0.209 1.00 8.32 ±1.64 8.22 ±1.90 8.63 ±1.69 9.26 ±9.44 1.00 1.00 0.54/ 0.589 1.00 2.60 ±0.54 2.40 ±0.68 2.37 ±0.74 2.53 ±1.72 0.816 1.00 0.215/ 0.83 1.00 1.43± 0.22 1.43 ±0.18 1.31 ±0.27 1.36 ±0.25 1.00 1.00 -1.35/ 0.179 0.065 ±1.00 ±0.89 ±1.42 ±1.21 0.411 1.34 1.26 1.84 1.54 1.00 0.961 0.824/ 0.08}\tabcellsep Volume XXI Issue VI Version I\\
\multicolumn{7}{l}{Controls In table-3 shows thyroid hormone status in diabetic and control subjects. Mean±SD of TT3; (ngm/dl) in controls Type-2 Diabetes mellitus (88.91±15.88) and in diabetic subjects (84.27±22.29) was not statistically significant to each other (p=0.209). Clinical history Number Percentage Number Percentage Sex Male 53 53 52 52 female 47 47 48 48 Type of work Sedentary 90 90 84 84 Physical work 10 10 16 16 Exercise Regular 37 37 23 23 Irregular 63 63 57 57 Mean±SD of TT4 (µgm/dl) in control subjects was 8.32±1.64 and in the diabetic subjects was 9.26±1.44, which is almost similar in both groups (p= 0.589). FT3 (pgm/ml) in control subjects was 2.60±0.54 and in diabetics was 2.534±1.72 (p= 0.830). FT4 (ngm dl) in control subjects was 1.43±0.22 and in diabetics subjects 1.36±0.25. (p 0.179). TSH (µlu/ml) in control subjects was 1.34±1.00 and in diabetic subjects 1.54±1.21. (p: 0.411). FT3; FT4 and TSH showed no significant difference between control and diabetic subjects.}\tabcellsep ( D D D D ) K Medical Research\\
\multicolumn{7}{l}{No Exercise Smoker Groups Non Smoker Groups with Low level of Thyroid hormone Smoking Past Smoker Groups with Normal level of Thyroid hormone 93.81±16.91 0 0 7 7 TT3 90 90 58.46±12.32 3 3 FH diabetes Present 53 53 T/p value -11.45/0.0001 -6.83/0.0001 -6.018/0.0001 20 20 20 FT3 TSH 20 70 1.31±0.44 0.50±0.49 70 10 2.53±0.59 1.50±0.86 10 65 65 Absent 47 47 23 (Results are expressed as mean±SD, p value was calculated using ANOVA Bonferrony, t/p value was calculated using unpaired 't' 23 FH HTN Present 50 50 48 48 test)}\\
\multicolumn{7}{l}{Absent Table-4 showed that the mean serum TT3 in patients with low T3 syndrome groups of patients and in patients with 50 50 36 36 FH obesity Present 44 44 46 normal values of TT3 were 58.46±12.32 and 93.81±16.91 respectively which was statistically significant (p=0.0001) 46 Absent 56 56 54 between the two groups. Mean Serum TSH level in low TSH group was 0.47±0.395 and in normal TSH group was 54 FH CAD Present 27 27 24 1.50±0.86 which was statistically different significantly (p=0.0001) from each other. Serum FT3 levels in low FT3 24 Absent 73 73 52 groups and normal FT3 groups of patients were 1.31±0.44 and 2.53±0.59 respectively which was statistically 52 FH CVD Present 24 24 27 27 different between the two groups.}\\
\tabcellsep \tabcellsep \tabcellsep Absent\tabcellsep 76\tabcellsep 76\tabcellsep 50\tabcellsep 50\\
\tabcellsep \multicolumn{2}{l}{H/O CAD}\tabcellsep Present\tabcellsep 4\tabcellsep 4\tabcellsep 38\tabcellsep 38\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep © 2021 Global Journals\end{longtable} \par
  {\small\itshape [Note: **(MC=Male control, FC= Female Control, TC= Total Control, MD=Male Diabetic, FD= Female Diabetic, TD=Total Diabetic)]} 
\caption{\label{tab_3}Table - 2}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4} \par 
\begin{longtable}{P{0.2774878640776699\textwidth}P{0.11656553398058252\textwidth}P{0.04848300970873787\textwidth}P{0.05467233009708738\textwidth}P{0.05879854368932039\textwidth}P{0.03610436893203883\textwidth}P{0.0433252427184466\textwidth}P{0.0453883495145631\textwidth}P{0.0845873786407767\textwidth}P{0.0845873786407767\textwidth}}
\tabcellsep \multicolumn{8}{l}{Table-5: Thyroid hormone pictures in diabetic subjects according to HbA1c}\tabcellsep \\
Groups\tabcellsep TT 3\tabcellsep TT 4\tabcellsep FT 3\tabcellsep FT 4\tabcellsep TSH\tabcellsep FPG\tabcellsep HbA1c\tabcellsep S Insulin\tabcellsep Serum C-Peptide\\
\multicolumn{2}{l}{Group A, N=13 78.42±}\tabcellsep 8.77±\tabcellsep 2.40\tabcellsep 1.37±\tabcellsep 1.37±\tabcellsep 5.97±\tabcellsep 6±\tabcellsep 5.9 (3.5-12.5)\tabcellsep 0.88\\
\tabcellsep 24.50\tabcellsep 1.15\tabcellsep ±0.59\tabcellsep 0.25\tabcellsep 0.25\tabcellsep 1.8\tabcellsep 0.56\tabcellsep \tabcellsep (0.11-5.1)\\
\multicolumn{2}{l}{Group B, N=15 89.71±}\tabcellsep 8.00\tabcellsep 2.35±\tabcellsep 1.22±\tabcellsep 1.90±\tabcellsep 7.7±\tabcellsep 7.37±\tabcellsep 8.0 (3.2-16.3)\tabcellsep 0.71\\
\tabcellsep 24.33\tabcellsep ± 1.53\tabcellsep 0.61\tabcellsep 0.27\tabcellsep 1.40\tabcellsep 1.9\tabcellsep 0.32\tabcellsep \tabcellsep (0.12-2.1)\\
Group C, n=72\tabcellsep 84.19\tabcellsep 8.45\tabcellsep 2.35±\tabcellsep 1.39±\tabcellsep 1.41±\tabcellsep 12.39±\tabcellsep 10.84±\tabcellsep 7.9 (19-48.9)\tabcellsep 0.74\\
\tabcellsep ±21.51\tabcellsep ±1.95\tabcellsep 0.73\tabcellsep 0.24\tabcellsep 1.11\tabcellsep 4.5\tabcellsep 1.89\tabcellsep \tabcellsep (0.06-3.6)\\
\tabcellsep \tabcellsep \tabcellsep P value\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{U/p value}\\
A vs B\tabcellsep 0.554\tabcellsep 0.773\tabcellsep 0.255\tabcellsep \multicolumn{2}{l}{0.774 0.135}\tabcellsep 0.749\tabcellsep 0.09\tabcellsep 75/0.30\tabcellsep 88.5/0.67\\
A vs C\tabcellsep 1.000\tabcellsep 1.000\tabcellsep 1.000\tabcellsep \multicolumn{2}{l}{1.000 1.000}\tabcellsep 0.000\tabcellsep 0.000\tabcellsep 343/0.13\tabcellsep 392/0.35\\
B vs C\tabcellsep 1.000\tabcellsep 1.000\tabcellsep 1.000\tabcellsep 0.97\tabcellsep 0.862\tabcellsep 0.000\tabcellsep 0.000\tabcellsep 513/0.76\tabcellsep 469/0.42\\
\multicolumn{7}{l}{(Group A=HbA1c < 7\%, Group B=HbA1c 7\%-8\%, Group C=HbA1c > 8\%)}\tabcellsep \tabcellsep \tabcellsep \\
\multicolumn{10}{l}{(P value was calculated using one way analysis of variance, U/p value was calculated using Non-parametric Mann Whitney U test.)}\end{longtable} \par
 
\caption{\label{tab_4}Table 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{6} \par 
\begin{longtable}{P{0.09608695652173913\textwidth}P{0.11530434782608696\textwidth}P{0.12417391304347827\textwidth}P{0.09313043478260868\textwidth}P{0.06504347826086956\textwidth}P{0.0768695652173913\textwidth}P{0.09460869565217392\textwidth}P{0.04582608695652174\textwidth}P{0.09460869565217392\textwidth}P{0.04434782608695652\textwidth}}
\multicolumn{2}{l}{Groups Serum Insulin}\tabcellsep Serum C peptide\tabcellsep FPG mg/dl\tabcellsep HbA1c\%\tabcellsep TT 3\tabcellsep TT 4\tabcellsep FT 3\tabcellsep FT 4\tabcellsep TSH\\
BMI A\tabcellsep 6.0 (1.9-38.0)\tabcellsep 0.74(0.06-3.62)\tabcellsep \multicolumn{2}{l}{11.77±5.18 10.35±2.63}\tabcellsep 81.45\tabcellsep 8.51±\tabcellsep 2.31±\tabcellsep 1.41±\tabcellsep 1.28\\
N=55\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep ±20.70\tabcellsep 1.77\tabcellsep 0.68\tabcellsep 0.26\tabcellsep ±0.89\\
BMI B\tabcellsep 8.6 (2.3-48.9)\tabcellsep 0.76(0.12-5.11)\tabcellsep 9.66±3.79\tabcellsep 8.83±2.01\tabcellsep 89.54±\tabcellsep 8.46±\tabcellsep 3.02±\tabcellsep 1.32±\tabcellsep 1.78\\
N=35\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 24.58\tabcellsep 1.78\tabcellsep 2.72\tabcellsep 0.26\tabcellsep ±1.51\\
BMI C\tabcellsep 14.9 (4.9-21.5)\tabcellsep 0.94(0.20-2.13)\tabcellsep 9.96±3.30\tabcellsep 9.10±2.01\tabcellsep 81.33±\tabcellsep 7.74±\tabcellsep 2.00±\tabcellsep 1.29±\tabcellsep 2.09\\
N=10\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 20.62\tabcellsep 2.15\tabcellsep 0.56\tabcellsep 0.18\tabcellsep ±1.30\\
\tabcellsep u/p value\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{P Value}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
A Vs B\tabcellsep 710/0.036\tabcellsep 811/0.21\tabcellsep 0.108\tabcellsep .013\tabcellsep 0.285\tabcellsep \multicolumn{2}{l}{1.000 0.164}\tabcellsep \multicolumn{2}{l}{0.721 0.160}\\
A vs C\tabcellsep 140/0.014\tabcellsep 219/0.30\tabcellsep 0.761\tabcellsep .399\tabcellsep 1.000\tabcellsep \multicolumn{2}{l}{1.000 1.000}\tabcellsep \multicolumn{2}{l}{0.651 1.000}\\
B vs C\tabcellsep 120/0.13\tabcellsep 172/0.93\tabcellsep 1.000\tabcellsep 1000\tabcellsep 0.913\tabcellsep \multicolumn{2}{l}{1.000 0.288}\tabcellsep \multicolumn{2}{l}{1.000 1.000}\end{longtable} \par
 
\caption{\label{tab_5}Table 6 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{7} \par 
\begin{longtable}{P{0.07763938315539738\textwidth}P{0.11998813760379595\textwidth}P{0.1784697508896797\textwidth}P{0.04436536180308422\textwidth}P{0.033274021352313166\textwidth}P{0.14015421115065244\textwidth}P{0.11595492289442468\textwidth}P{0.11393831553973903\textwidth}P{0.026215895610913406\textwidth}}
\multicolumn{2}{l}{Groups}\tabcellsep FPG\tabcellsep HbA1c\tabcellsep BMI\tabcellsep \multicolumn{3}{l}{\% body Fat Total Fat Mass Fasting Serum Insulin}\\
BMI A\tabcellsep Low T 3\tabcellsep \multicolumn{3}{l}{14.24±7.13 10.74±3.15 23.16±1.39}\tabcellsep 23.46±5.45\tabcellsep 7.6 (1.92-18.3)\tabcellsep 7.6 (1.92-18.3)\\
\tabcellsep \multicolumn{4}{l}{Normal T 3 1018±3.61 10.18±2.39 22.74±1.89}\tabcellsep 25.48±5.84\tabcellsep 5.55 (1.9-38.0)\tabcellsep 5.55 (1.9-38.0)\\
\tabcellsep t/p value\tabcellsep \multicolumn{3}{l}{1.96/0.064 0.721/0.474 0.813/0.420}\tabcellsep -1.210/0.23\tabcellsep u/p value\tabcellsep u/p value\tabcellsep *281/0.44\\
BMI B\tabcellsep Low T 3\tabcellsep 9.55±4.40\tabcellsep \multicolumn{2}{l}{9.08/±2.41 27.19±1.25}\tabcellsep 33.31±4.83\tabcellsep 8.0 (2.3-47)\tabcellsep 8.0 (2.3-47)\\
\tabcellsep \multicolumn{2}{l}{Normal T3 9.70±3.68}\tabcellsep 8.76±1.93\tabcellsep 27.33±1.45\tabcellsep 3.72±5.82\tabcellsep 8.8 (3.5-48.9)\tabcellsep 8.8 (3.5-48.9)\\
\tabcellsep t/p value\tabcellsep \multicolumn{3}{l}{-.094/0.925 0.380/0.706 -0.233/0.817}\tabcellsep 1.146/0.26\tabcellsep u/p value\tabcellsep u/p value\tabcellsep *99/0.72\\
BMI C\tabcellsep Low T 3\tabcellsep \multicolumn{2}{l}{10.45±0.64 9.55±1.34}\tabcellsep 33.41±3.61\tabcellsep 36.85±6.29\tabcellsep 13.4 (5.3-21.5)\tabcellsep 13.4 (5.3-21.5)\\
\tabcellsep Normal T 3\tabcellsep 9.84±3.73\tabcellsep 8.99±2.54\tabcellsep 31.63±1.60\tabcellsep 37.30±4.10\tabcellsep 14.9 (4.9-20.8)\tabcellsep 14.9 (4.9-20.8)\\
\tabcellsep t/p value\tabcellsep \multicolumn{3}{l}{0.222/0.83 0.294/0.776 1.144/0.286}\tabcellsep -.182/0.901\tabcellsep 0.335/0.726\tabcellsep u/p value\tabcellsep *7.0/0.79\\
\multicolumn{5}{l}{(BMI A=BMI upto 25). (BMI B=BMI 25.1-30). (BMI C=BMI>30)}\tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_6}Table 7 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{8} \par 
\begin{longtable}{P{0.01220626631853786\textwidth}P{0.14203655352480418\textwidth}P{0.1564621409921671\textwidth}P{0.0577023498694517\textwidth}P{0.1398172323759791\textwidth}P{0.10763707571801566\textwidth}P{0.1154046997389034\textwidth}P{0.11873368146214099\textwidth}}
\tabcellsep Groups\tabcellsep FPG\tabcellsep HbA1c\tabcellsep Fasting S. Insulin\tabcellsep BMI\tabcellsep \%Body Fat\tabcellsep Total Fat Mass\\
TT 3\tabcellsep LowTT 3 (n=27)\tabcellsep \multicolumn{2}{l}{12.57±6.44 10.16±2.89}\tabcellsep 7.7(1.9-47.0)\tabcellsep 25.11±3.35\tabcellsep 27.37±3.74\tabcellsep 18.12±5.93\\
\tabcellsep Normal TT 3 (n=73)\tabcellsep 10.21±3.63\tabcellsep 9.52±2.32\tabcellsep 8(1.9-48.9)\tabcellsep 25.41±3.45\tabcellsep 28.72±6.83\tabcellsep 19.14±6.13\\
\tabcellsep t/p value\tabcellsep 2.30/0.024\tabcellsep 1.572/0.119\tabcellsep 972/0.92*\tabcellsep -0.384/0.702\tabcellsep -0.856/0.394\tabcellsep -0.753/0.453\\
FT 3\tabcellsep LowFT 3 (n=12)\tabcellsep 11.45±5.09\tabcellsep 9.98±2.43\tabcellsep 7.4(4.4-38.0)\tabcellsep 26.59±3.52\tabcellsep 30.42±7.24\tabcellsep 21.42±5.94\\
\tabcellsep Normal FT 3 (n=88)\tabcellsep 10.77±4,61\tabcellsep 9.66±2.51\tabcellsep 7.8(1.9-48.9)\tabcellsep 25.16±3.33\tabcellsep 28.07±6.91\tabcellsep 18.52±6.03\\
\tabcellsep t/p value\tabcellsep \multicolumn{2}{l}{0.475/0.636 0.426/0.671}\tabcellsep 480.5/0.61*\tabcellsep 1.357/0.178\tabcellsep 1.096/0.276\tabcellsep 1.562/0.122\\
TSH\tabcellsep Low TSH (n=12)\tabcellsep \multicolumn{2}{l}{12.24±4.16 10.86±2.48}\tabcellsep 8.3(1.9-48.9)\tabcellsep 25.27±1.82\tabcellsep 30.19±7.65\tabcellsep 19.98±5.0\\
\tabcellsep Normal TSH (n=88)\tabcellsep 10.81±4.78\tabcellsep 9.65±2.48\tabcellsep 7.7(1.96-47.0)\tabcellsep 25.21±3.65\tabcellsep 27.63±6.66\tabcellsep 18.40±6.20\\
\tabcellsep t/p value\tabcellsep \multicolumn{2}{l}{0.986/0.327 1.573/0.137}\tabcellsep 461.5/0.48*\tabcellsep 0.449/0.218\tabcellsep 1.524/0.782\tabcellsep 0.982/0.624\end{longtable} \par
 
\caption{\label{tab_7}Table 8 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{-} \par 
\begin{longtable}{}
\end{longtable} \par
 
\caption{\label{tab_8}Table - 8}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{}
\end{longtable} \par
  {\small\itshape [Note: group and TSH with low values of thyroid hormones groups and TSH among the diabetic subjects, 27 diabetic patients were found to have low TT 3 below the lower limit of normal range than that of their normal counterpart which was significant at p=0.0001 level (table-4 and 8), 12 patients were found to have serum]} 
\caption{\label{tab_9}}\end{figure}
 			\footnote{© 2021 Global Journals} 		 		\backmatter   			 
\subsection[{Acknowledgement and Disclosure}]{Acknowledgement and Disclosure} 
\subsection[{I hereby acknowledge and express my honor and gratitude}]{I hereby acknowledge and express my honor and gratitude}\par
To Professor Hajera Mahtab, the supervisor of the research work, for her guidance, advise and contribution for selection of the title of the research work, designing of the protocol and all through contribution to complete the work.\par
To Professor Liaquat Ali, my co-supervisor of the research work for constant guidance, constructive criticism, developing scientific and research interest within me and also arranging the fund for completing the research work throughout the whole tenure of the work.\par
To Dr. Samira Jamal for data collection, data entry and compiling the data, preparation of the manuscript and all through contribution for the work.\par
To Sheikh Raihan for data entry, data compilation, data analysis and manuscript preparation during the whole period of the work. Dr. Mohamed Emran for data collection, data compilation and preparation of the manuscript wholeheartedly throughout the work.\par
To Omar Faroque for giving all through for laboratory specimen collection, specimen preparation and preservation and finally laboratory analysis of all biochemical parameters throughout the whole period of the work. 			  			  				\begin{bibitemlist}{1}
\bibitem[ Diabetes Mellitus. J. Evolution Med. Dent. Sci ()]{b30}\label{b30} 	 		\textit{},  	 	 		\textit{Diabetes Mellitus. J. Evolution Med. Dent. Sci}  		2016. 5  (54)  p. .  	 
\bibitem[ Diabetes Mellitus. International Journal of Scientific Study ()]{b2}\label{b2} 	 		\textit{},  	 	 		\textit{Diabetes Mellitus. International Journal of Scientific Study}  		2017. 5  (2)  p. .  	 
\bibitem[Kandasamy et al.]{b29}\label{b29} 	 		\textit{A Study on correlation between HbA1c levels with TSH levels in patients with Hypothyroidism and Type 2},  		 			N Kandasamy 		,  		 			T Rajendran 		,  		 			D H Vallathol 		,  		 			V Radhakrishnan 		,  		 			A B Mani 		,  		 			V Gurusamy 		.  		 	 
\bibitem[Wartofsky and Burman ()]{b11}\label{b11} 	 		‘Alterationin thyroid function in patients with systemic illnesses, the Euthyroid Sick Syndrome’.  		 			L Wartofsky 		,  		 			K D Burman 		.  	 	 		\textit{Endcr Review}  		1982. 3 p. .  	 
\bibitem[Radetti et al. ()]{b16}\label{b16} 	 		‘Altered adrenal and thyroid function in children with insulin dependent diabetes mellitus’.  		 			G Radetti 		,  		 			C Paganine 		,  		 			L Gentli 		,  		 			F Banbin 		,  		 			B Pasquino 		,  		 			M Zachmann 		.  	 	 		\textit{Acta Diabetol}  		1994. 31  (3)  p. .  	 
\bibitem[Lu ()]{b15}\label{b15} 	 		‘Changes in circulating lymphocyte triiodothyronine receptorin diabetes mellitus’.  		 			G Lu 		.  	 	 		\textit{Chung Hua I Chih Hsuch Tsa}  		1993. 73  (9)  p. .  	 
\bibitem[Castro et al. ()]{b17}\label{b17} 	 		‘Changes in the thyroid hormone picturethat may be found in severely decompensated type2 diabetics’.  		 			N Castro 		,  		 			V Seafidi 		,  		 			T Borsellero 		.  	 	 		\textit{Menerva Med}  		1991. 82  (1-2)  p. .  	 
\bibitem[Bagchi et al. ()]{b20}\label{b20} 	 		‘Decrease thyroid response to thyrotropin in type2 diabetes mellitus’.  		 			N Bagchi 		,  		 			N Palaniswami 		,  		 			H Desai 		,  		 			J Fellicetta 		,  		 			T R Brown 		.  	 	 		\textit{Metabolism}  		1998. 37  (7)  p. .  	 
\bibitem[Tiwari and Roa ()]{b0}\label{b0} 	 		‘Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospectus’.  		 			A K Tiwari 		,  		 			J M Roa 		.  	 	 		\textit{Current Science}  		2002. 83  (1)  p. .  	 
\bibitem[Donckier ()]{b33}\label{b33} 	 		‘Endocrine diseases and diabetes’.  		 			J E Donckier 		.  	 	 		\textit{Pickup JC},  				 (Williams G)  		2003. p. .  	 	 (Text book of diabetes mellitus) 
\bibitem[Chopra ()]{b9}\label{b9} 	 		‘Euthyroid Sick Syndrome, abnormalities in circulating thyroid hormones and thyroid hormone Reference physiology in non-thyroidal illness syndrome’.  		 			I J Chopra 		.  	 	 		\textit{Med Grand Round 1}  		1996. p. .  	 
\bibitem[Pasupathi et al. ()]{b32}\label{b32} 	 		‘Evaluation of oxidative stress, antioxidant and thyroid hormone status in patients with diabetes mellitus’.  		 			P Pasupathi 		,  		 			V Chandrashekar 		,  		 			Senthil Kumar 		,  		 			U 		.  	 	 		\textit{J Medicine}  		2009. 10 p. .  	 
\bibitem[Udiong et al. ()]{b31}\label{b31} 	 		‘Evaluation of Thyroid Function in Diabetes Mellitus in Calabar’.  		 			Cej Udiong 		,  		 			A E Udoh 		,  		 			M E Etukudoh 		.  	 	 		\textit{Nigeria. Indian Journal of Clinical Biochemistry}  		2007. 22  (2)  p. .  	 
\bibitem[Singh et al. ()]{b28}\label{b28} 	 		‘Frequency of thyroid dysfunction among diabetes in Punjabi population’.  		 			G Singh 		,  		 			V Gupta 		,  		 			A K Sharma 		,  		 			N Gupta 		.  	 	 		\textit{Adv. Biores}  		2011. p. .  	 
\bibitem[Greenspan et al. ()]{b23}\label{b23} 	 		 			F S Greenspan 		,  		 			Fs Greenspan 		,  		 			; A Lange Medical Strewter 		,  		 			Book 		.  		\textit{The Thyroid gland in: Basic and Clinical Endocrinology},  				1997. p. .  	 	 (5 th edition) 
\bibitem[David and Ath ()]{b27}\label{b27} 	 		‘Initial management of glycemia in type-2 diabetes mellitus’.  		 			M David 		,  		 			M D Ath 		.  	 	 		\textit{NEJM}  		2012. 347  (17)  p. .  	 
\bibitem[Chopra ()]{b10}\label{b10} 	 		‘Non thyroidal illness syndrome or Euthyroid Sick Syndrome’.  		 			I J Chopra 		.  	 	 		\textit{End0cr Pract}  		1996. 2 p. .  	 
\bibitem[Schnack and Schernthner ()]{b19}\label{b19} 	 		‘pituitary-thyrotroph functions and thyroid hormones in long standing type2 diabetic before and after insulin treatment’.  		 			C Schnack 		,  		 			G Schernthner 		.  	 	 		\textit{Exp Endocrinol}  		1986. 90  (2)  p. .  	 
\bibitem[Report of the expert committee on the diagnosis and classification of Diabetes Mellitus Diabetes Care ()]{b24}\label{b24} 	 		‘Report of the expert committee on the diagnosis and classification of Diabetes Mellitus’.  	 	 		\textit{Diabetes Care}  		2000. 23  (1)  p. .  	 
\bibitem[Kabadi ()]{b14}\label{b14} 	 		‘Serum T3 and Reverse T3 concentration, indices of metabolic control in diabetes mellitus’.  		 			U M Kabadi 		.  	 	 		\textit{Diabetes Res}  		1986. 3  (8)  p. .  	 
\bibitem[Srinidhi et al. ()]{b5}\label{b5} 	 		‘Shrinidhi et al Thyroid function in type 2 diabetes mellitus and diabetic nephropathy’.  		 			R Srinidhi 		,  		 			K J Ashok 		,  		 			K Prajna 		,  		 			K S Shobith 		,  		 			R Tirthal 		.  	 	 		\textit{Journal of Clinical and Diagnostic Research}  		2013. 7  (8)  p. .  	 
\bibitem[Sreelatha et al.]{b1}\label{b1} 	 		 			M Sreelatha 		,  		 			V S Kumar 		,  		 			G C Shekar 		,  		 			V Shekar 		.  		\textit{Study of Thyroid Profile in Patients with Type},  				 	 
\bibitem[Shekhar and Biswajit]{b26}\label{b26} 	 		‘Status of Thyroid Profile in Type-2 Diabetes Mellitus’.  		 			C Y Shekhar 		,  		 			Alwin S Biswajit 		,  		 			M 		.  	 	 		\textit{Journal of Nobel Medical College. 2012}  		1  (2)  p. .  	 
\bibitem[Alok et al. ()]{b6}\label{b6} 	 		‘Study of thyroid dysfunction in type 2 diabetes mellitus patients of Agra city’.  		 			M Alok 		,  		 			K K Pawan 		,  		 			P M Kamla 		,  		 			K Raj 		.  	 	 		\textit{International Journal of Biomedical Research}  		2016. 7  (01)  p. .  	 
\bibitem[Mollah ()]{b21}\label{b21} 	 		\textit{Study of thyrometabolic state and autoimmune manifestation in MRDM},  		 			F H Mollah 		.  		1996.  	 	 (M Phil Thesis) 	 (IPGMR and BIRDEM) 
\bibitem[Steger and Rabe ()]{b18}\label{b18} 	 		‘The effect of diabetes mellitus on endocrine and reproductive function’.  		 			R W Steger 		,  		 			M B Rabe 		.  	 	 		\textit{ProcSoc Exp Biol Med}  		1997. 214  (1)  p. .  	 
\bibitem[Wu ()]{b4}\label{b4} 	 		‘Thyroid disease and diabetes’.  		 			P Wu 		.  	 	 		\textit{Clinical diabetes}  		2000. 18  (1)  p. .  	 
\bibitem[Shah ()]{b8}\label{b8} 	 		‘Thyroid disease in diabetes mellitus’.  		 			S N Shah 		.  	 	 		\textit{J Assoc Physicians India}  		1984. 32  (12)  p. .  	 
\bibitem[Sugure et al. ()]{b7}\label{b7} 	 		‘Thyroid disease in diabetics’.  		 			D D Sugure 		,  		 			M Mcevoy 		,  		 			M I Drury 		.  	 	 		\textit{Postgrad Med J}  		1999. p. .  	 
\bibitem[Uppal et al. ()]{b3}\label{b3} 	 		‘Thyroid Disorders in Patients of Type 2 Diabetes Mellitus’.  		 			V Uppal 		,  		 			Chittranjanv 		,  		 			K B Gurdeep 		,  		 			V Anil 		,  		 			D Basu 		.  	 	 		\textit{Ind J ClinBiochem}  		2013. 28  (4)  p. .  	 
\bibitem[Chopra et al. ()]{b12}\label{b12} 	 		‘Thyroid function in Non-thyroidal Ilness’.  		 			I J Chopra 		,  		 			J M Hershman 		,  		 			W M Pardridge 		,  		 			J T Neology 		.  	 	 		\textit{Ann Intern Med}  		1983. 98 p. .  	 
\bibitem[Nunez et al. ()]{b13}\label{b13} 	 		‘Thyroid function study in patients with Diabetes Mellitus’.  		 			A M Nunez 		,  		 			E G Sarmiento 		,  		 			P E Martin 		,  		 			C E Miguel 		,  		 			J C Pinilla 		,  		 			A M Cabello 		.  	 	 		\textit{Ann Med Intern}  		1990. 7  (6)  p. .  	 
\bibitem[Bhu et al. ()]{b22}\label{b22} 	 		‘Thyroid in NIDDM’.  		 			N Bhu 		,  		 			H S Meena 		,  		 			J Jailal 		.  	 	 		\textit{J Assoc Physicians India}  		1988. 36  (12)  p. .  	 
\bibitem[Chalmers ()]{b25}\label{b25} 	 		‘Who and International society of HTN guidelines for the management of Hypertension’.  		 			J Chalmers 		.  	 	 		\textit{J Hypertens}  		1999. 17 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
